| Bioactivity | Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2]. |
| Invitro | Orticumab (10 μg/mL；24 小时) 增加 oxLDL 刺激后体外培养的 PBMC 中的 CD14+ ICOS-L+ 群体[1]。 |
| In Vivo | Orticumab (10 毫克/小鼠；腹腔注射；每周一次，持续 3 周) 减少主动脉弓中的动脉粥样硬化，减少 CD68 巨噬细胞瓣膜下斑块染色[1]。 Animal Model: |
| Name | Orticumab |
| CAS | 1314241-10-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863. [2]. Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05. |